MRNA Moderna, Inc.

194.04USD-2.65%Mkt Cap: 80.65B USDP/E: —

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal in…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap80.65B USD
Enterprise Value79.71B USD
Revenue (TTM)2.52B USD
Gross Profit1.05B USD
Net Income (TTM)-2.82B USD
Revenue/Share6.37 USD
Last Price194.04 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees4.7K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-47.59
PEG—
EV/EBITDA-44.71
EV/Revenue31.57
P/S31.94
P/B11.78
EPS (TTM)-7.04 USD
EPS (Forward)-4.19 USD
52W Range
22.2866% of range280.80
52W High280.80 USD
52W Low22.28 USD
Profitability
Gross Margin54.84%
Oper. Margin-80.79%
EBITDA Margin-70.61%
Profit Margin-146.83%
ROE-32.62%
ROA-22.87%
ROIC-73.97%
ROCE-29.70%
Growth
Revenue Growth29.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.87B USD
CapEx (TTM)202.00M USD
FCF Margin-23.15%
FCF Yield-0.72%
Net Debt-942.00M USD
Net Debt/EBITDA0.53
Net Debt/FCF—
Balance Sheet
Debt/Equity0.15
Current Ratio3.62
Quick Ratio3.32
Book Value/Sh16.92 USD
Cash/Share12.78 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.9 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)164.53 USD
Upside (mean)-15.2%
Target Range45.00 USD – 305.00 USD
45.00-15.2% to mean305.00
# Analysts19
Ownership
Shares Out.404.62M
Float377.36M
Insiders7.25%
Institutions77.80%
Short Interest
Short Ratio1.8d
Short % Float9.99%
Short % Out.8.20%
Shares Short33.19M
Short (prev mo.)30.86M
Technical
SMA 50205.61 (-5.6%)
SMA 20098.86 (+96.3%)
Beta1.17
S&P 52W Chg12.00%
Avg Vol (30d)14.49M
Avg Vol (10d)9.69M
Technical Indicators
RSI (14)42.7
MACD1.2858
MACD Signal8.5717
MACD Hist.-7.2859
BB Upper269.23 USD
BB Middle225.51 USD
BB Lower181.80 USD
BB Width38.77%
ATR (14)18.35 USD
Vol Ratio (20d)0.61x

About Moderna (NASDAQ: MRNA)

›

Moderna (NASDAQ: MRNA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 4,700 employees.

The shares were at 194.04 USD on 20 November 2026, up 719.3% over 52 weeks. Its 52-week range is 22.28 USD to 280.80 USD: the price is 30.9% below the high and 770.9% above the low.

Its market capitalisation is 80.65B USD.

Moderna reports return on equity of -32.6%, an operating margin of -80.8% and revenue up 29.2% year over year.

It holds more cash than debt, a net cash position of 942.00M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 19 analysts cover the stock, with an average rating of Hold; their mean price target of 164.53 USD is 15.2% below the current price. The next earnings report is expected on 12 February 2027.